Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript
Milestone Pharmaceuticals: Here Comes The Revenue Ramp
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Why Milestone Pharmaceuticals Stock Wilted on Wednesday
Milestone Pharmaceuticals Q1 Earnings Call Highlights
Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript
Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales
Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Average Rating of “Moderate Buy” from Analysts
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
Milestone Pharmaceuticals Inc. (MIST) Q4 2025 Earnings Call Transcript
Why Milestone Pharma Stock Is Taking A Dive Today
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Milestone Pharmaceuticals (NASDAQ:MIST) versus Rani Therapeutics (NASDAQ:RANI) Head to Head Review
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Given Consensus Recommendation of “Moderate Buy” by Analysts
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alector (NASDAQ:ALEC) and Milestone Pharmaceuticals (NASDAQ:MIST) Critical Review
All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong Buy
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of “Moderate Buy” from Brokerages
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Milestone® Pharmaceuticals to Present at Upcoming Conferences
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
Milestone Pharmaceuticals Announces Proposed Public Offering